Compound for the Treatment of Enteroviruses
AssigneeBiota Scientific Management Pty Ltd.
InventorsJohan NEYTS, Armando De Palma, Hendrik Jan Thibaut, Pieter Leyssen, Simon Tucker
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.
Claims23
A method for treating, alleviating, or reducing an enteroviral infection caused by a serotype of one or more viruses selected from the group consisting of enterovirus, poliovirus, Human enterovirus B, Human enterovirus C and Human enterovirus D, comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject suffering from said infection, and further comprising administering a second enteroviral agent.
A composition comprising 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxyl-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof and a second anti-enteroviral agent.
A composition comprising 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxyl-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof and interferon, and wherein one or both of the first and second components optionally comprise a pharmaceutically-acceptable adjuvant, diluent or carrier.
A kit comprising a first component and a second component, wherein each component of the kit is provided in a form suitable for administration in conjunction with the other component, the first component comprising 3-ethoxy-6-{241-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxyl-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof, and the second component comprising a second anti-enteroviral agent, and wherein one or both of the first and second components optionally comprise a pharmaceutically-acceptable adjuvant, diluent or carrier.
A method for treating, alleviating, or reducing an enteroviral infection comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject suffering from said infection, and further comprising administering a second enteroviral agent selected from the group consisting of a capsid binder, a 3C protease inhibitor, a 3A targeting compound, interferon and a vaccine.
A method for treating, alleviating, or reducing an enteroviral infection comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject suffering from said infection, and further comprising administering interferon.
Dependencies are inferred from the claim text.